Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19552155 | 1.00 | HTT (0.35) | HTTKMT2ALMNAADORA3ADORA2A | |
| SCHEMBL8721237 | 0.73 | HTT (0.39) | HTTADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29810776 | 0.71 | PDE4B (0.35) | HTTKMT2ALMNAMEN1 | |
| SCHEMBL27219170 | 0.70 | PKM (0.54) | LMNA | |
| SCHEMBL27219168 | 0.70 | PKM (0.54) | LMNA | |
| SCHEMBL27219275 | 0.70 | PKM (0.54) | LMNA | |
| SCHEMBL29810763 | 0.69 | TK1 (0.37) | KMT2ALMNA | |
| SCHEMBL15046620 | 0.62 | KDM4E (0.50) | HTTKMT2ALMNATGFBR1MEN1 | |
| SCHEMBL15046561 | 0.62 | KDM4E (0.50) | HTTKMT2ALMNATGFBR1MEN1 | |
| SCHEMBL15046635 | 0.62 | KDM4E (0.50) | HTTKMT2ALMNATGFBR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452469-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191112-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | WO | claimed |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | GLS, TNNI3, NAT1 | HTT 2209/4885KMT2A 2415/4885LMNA 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.